Insmed, Inc. $INSM Shares Purchased by Calamos Advisors LLC

Key Points

• Calamos Advisors increased its Insmed stake by 251% in the third quarter, buying 21,352 shares to hold 29,859 shares valued at about $3.4 million.
• Director David Brennan sold 25,000 shares at an average price of $124, reducing his position by 38.92%; Insmed insiders collectively own 2.10% of the company.
• Analysts’ consensus rating is Moderate Buy, with a $196.52 average price target. In its latest quarter, Insmed’s revenue rose 268.4% year over year to $524.43 million, topping estimates, while its per-share loss was wider than expected.

Calamos Advisors LLC lifted its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 251.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,859 shares of the biopharmaceutical company's stock after purchasing an additional 21,352 shares during the period. Calamos Advisors LLC's holdings in Insmed were worth $3,408,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in INSM. Virginia Estate & Retirement Planning Advisors Inc. acquired a new position in Insmed in the third quarter valued at approximately $29,000. SBI Securities Co. Ltd. boosted its holdings in shares of Insmed by 69.4% during the 3rd quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 143 shares in the last quarter. CX Institutional acquired a new stake in shares of Insmed during the 3rd quarter worth approximately $46,000. Harbor Investment Advisory LLC acquired a new stake in shares of Insmed during the 2nd quarter worth approximately $52,000. Finally, Versant Capital Management Inc increased its stake in shares of Insmed by 118.9% in the 3rd quarter. Versant Capital Management Inc now owns 648 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 352 shares in the last quarter.

Insider Transactions at Insmed

In other Insmed news, Director David Brennan sold 25,000 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.10% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on INSM shares. Stifel Nicolaus set a $195.00 target price on shares of Insmed in a research report on Thursday, October 29th. Bank of America restated a "buy" rating and issued a $207.00 price target on shares of Insmed in a report on Monday, October 12th. Morgan Stanley decreased their price target on shares of Insmed from $218.00 to $213.00 and set an "overweight" rating for the company in a research note on Wednesday, October 21st. HC Wainwright started coverage on shares of Insmed in a report on Wednesday, November 4th. They set a "buy" rating and a $220.00 price objective on the stock. Finally, Wells Fargo & Company upped their price objective on shares of Insmed from $161.00 to $169.00 and gave the company an "overweight" rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $196.52.

Insmed Trading Down 0.0%

Shares of Insmed stock opened at $114.40 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86. Insmed, Inc. has a 52 week low of $90.39 and a 52 week high of $212.75. The stock has a 50 day moving average price of $111.21 and a two-hundred day moving average price of $124.36. The stock has a market capitalization of $25.10 billion, a PE ratio of -40.57 and a beta of 0.83.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The firm had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. During the same period in the previous year, the company earned ($1.75) earnings per share. Insmed's revenue for the quarter was up 268.4% compared to the same quarter last year. As a group, equities analysts anticipate that Insmed, Inc. will post -1.86 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr.

Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.